Stocks
Longeveron Sets August 2026 ELPIS II Readout, Adopts Asset-Light Model
Longeveron (LGVN) targets an August 2026 readout for its ELPIS II study, simultaneously shifting to an asset-light partnering model under new leadership....
#biotech stocks 2 articles
Stocks
Biodesix Lifts 2026 Revenue Outlook to $108M-$114M
Biodesix (BDSX) raises its 2026 revenue forecast to $108M-$114M, driven by accelerated Q1 growth and expanded margins, targeting sustained adjusted EBITDA profitability.